CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Metastatic Castration-Resistant Prostate Cancer
Oncology Nursing News
Precision Medicine in Oncology
Special Reports in Personalized Cancer Care
SELECT A TOPIC
Hematologic Malignancies Medical Crossfire in NYC on July 14th! Register today!
<< View More Conferences
2018 Gastrointestinal Cancers Symposium
Oncology Conference Multimedia
View more videos >>
Dr. Chau on the Tolerability of Ramucirumab Plus Pembrolizumab in Gastric/GEJ Cancer
Dr. Bekaii-Saab Discusses QoL With Regorafenib Dose Escalation in mCRC
Dr. Overman on Updated Findings With Nivolumab in Metastatic CRC
Oncology Conference Articles
Nivolumab Alone or With Ipilimumab Provides Durable Benefit in MSI-H/dMMR mCRC
Data from the CheckMate-142 study support the use of nivolumab (Opdivo) alone or in combination with ipilimumab (Yervoy) for the treatment of patients with previously treated DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer.
Napabucasin Plus Pembrolizumab Shows Early Promise in mCRC
Combining the investigational oral cancer stem cell pathway inhibitor napabucasin with the PD-1 inhibitor pembrolizumab showed a signal of efficacy in the first 8 patients enrolled in a multicenter phase I/II trial of patients with metastatic colorectal cancer.
Pembrolizumab Promising After Sorafenib in Advanced HCC
Treatment with the PD-1 inhibitor pembrolizumab elicited promising progression-free survival and overall survival results in patients with advanced hepatocellular carcinoma who received previous treatment with sorafenib.
Cetuximab Plus Pembrolizumab Well Tolerated in RAS Wild-Type mCRC
The combination of cetuximab and pembrolizumab was found to be well tolerated in patients with
wild-type metastatic colorectal cancer.
Lenvatinib Plus Pembrolizumab or Nivolumab Active in Intrahepatic Cholangiocarcinoma
Combining lenvatinib (Lenvima) with PD-1 inhibitors had promising efficacy in patients with advanced intrahepatic cholangiocarcinoma, according to preliminary data from a single-center study.
Regorafenib Before Cetuximab Improves Survival in mCRC
Sequencing regorafenib before cetuximab showed superior overall survival compared with the reverse sequence in patients with metastatic colorectal cancer following failure of standard chemotherapy.
Nab-Paclitaxel/Gemcitabine Effective for Locally Advanced Pancreatic Cancer
Induction treatment with nab-paclitaxel plus gemcitabine demonstrated a time to treatment failure of 8.8 months for patients with newly diagnosed locally advanced pancreatic cancer.
Regorafenib Dose Escalation Superior in Metastatic CRC
Tanios Bekaii-Saab, MD, discusses the results and significance of the ReDOS study in metastatic colorectal cancer, as well as shared some insight on the Reverce trial.
CTC Assay Accurately Detects Precancerous Polyps
The CellMax biomimetic platform, a novel circulating tumor cell assay, was 84% to 88% accurate at detecting precancerous and cancerous colorectal lesions.
Nivolumab/Ipilimumab Combo Data Encouraging in Advanced GISTs
Nivolumab alone and in combination with ipilimumab induced responses in patients with heavily pretreated gastrointestinal stromal tumor.
Adding Ramucirumab to Frontline Chemo Does Not Improve Survival in Gastric Cancer
Adding ramucirumab to standard first-line chemotherapy significantly improved investigator-assessed progression-free survival compared with chemotherapy plus placebo in treatment-naive patients with HER2-negative gastric cancer.
Ramucirumab/Durvalumab Combination Shows Antitumor Activity in Gastric and GEJ Cancer
The combination of the VEGFR-2 inhibitor ramucirumab plus the anti-PD-L1 agent durvalumab demonstrated antitumor activity in patients with previously treated advanced gastric or gastroesophageal junction adenocarcinoma.
Trastuzumab Deruxtecan Active in HER2-Expressing Gastric Cancer
The novel investigational HER2-targeting antibody-drug conjugate trastuzumab deruxtecan showed promising antitumor activity in heavily pretreated patients with HER2-expressing gastric cancer.
Cabozantinib Improves OS, PFS in Advanced HCC
Treatment with cabozantinib improved median overall survival by 2.2 months compared with placebo for patients with previously treated advanced hepatocellular carcinoma.
FDA Approval in CRC, Priority Review in HCC, Encouraging Data in Myeloma Trial, and More
Ramalingam Reflects on Recent Advances in SCLC
Progress Continues in EGFR+ NSCLC Paradigm
Defining Precision Cancer Medicine the Right Way
MCL Researcher Highlights Future of CAR T-Cell Therapy, Other Approaches
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2018
Intellisphere, LLC. All Rights Reserved.